Therefore, targeting specific SP1 binding sites on PTEN for selective activation or inhibition may serve as a potential therapeutic strategy for kidney injury-related diseases, and the SP1/PTEN/Akt axis holds promise as a therapeutic approach for ischemia–reperfusion-induced AKI. The gene discussed is SP1; the disease is acute kidney injury.